MedTrace Logo

Does Progesterone Prevent Very Preterm Delivery in Twin Pregnancies?

NCT00329914 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 677

Last updated 2011-07-25

No results posted yet for this study

Summary

The purpose of the study is to determine whether a daily dose of 200 mg progesterone administered vaginally from 20-23 to 34 weeks' gestation will reduce the rate of preterm delivery amongst twin pregnancies.

Conditions

  • Preterm Delivery

Interventions

DRUG

Progesterone

Vaginal pessaries, 200 mg/day

DRUG

Placebo

Placebo pessaries containing peanut oil

Sponsors & Collaborators

  • The Danish Medical Research Council

    collaborator OTHER

  • The Danish Medical Society in Copenhagen

    collaborator UNKNOWN

  • AP Moeller Foundation

    collaborator OTHER

  • Rigshospitalet, Denmark

    lead OTHER

Principal Investigators

  • Line Rode, MD · Ultrasound Clinic 4002, Rigshospitalet

  • Ann Tabor, professor · Ultrasound Clinic 4002, Rigshospitalet

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30
Primary Completion
2009-02-28
Completion
2010-09-30

Countries

  • Austria
  • Denmark

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00329914 on ClinicalTrials.gov